Author Topic: NICE won't provide NHS funding for Ocrevus  (Read 162 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9821
  • MS diagnosed 1980
  • Location: Pacific Northwest
NICE won't provide NHS funding for Ocrevus
« on: April 06, 2018, 06:37:14 am »

In the UK, NICE (National Institute for Health and Care Excellence) is the organization that decides whether there will be National Health Service funding for a new drug. They've decided that Ocrevus isn't cost-effective enough to warrant use of NHS resources, based on the available evidence.  Ocrevus wasn't compared with all of the other available MS drugs--just with interferon beta-1a.

http://www.pharmatimes.com/news/nice_no_for_roches_ocrevus_1230626
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics

  Subject / Started by Replies Last post
1 Replies
236 Views
Last post June 14, 2017, 10:35:24 am
by agate
1 Replies
217 Views
Last post February 05, 2018, 04:11:07 pm
by agate
0 Replies
58 Views
Last post August 07, 2018, 04:01:32 pm
by agate
0 Replies
46 Views
Last post February 17, 2019, 09:46:10 pm
by agate
0 Replies
54 Views
Last post May 14, 2021, 07:55:23 am
by agate